Biomedical Engineering Reference
In-Depth Information
Overall this study showed for the first time that siRNA-mediated
innate immune activation unaccompanied by oncogene silencing has
significant but transient anti-tumour effects in HPV-driven cancers.
Our data suggests that a more potent and sustained anti-tumour
effect can be obtained by combining siRNA oncogene silencing
with innate immune recruitment. This is further supported by the
data showing abolition of the immunostimulation activity reduced
anti-tumour activity. With improvements to bi-functionality by
incorporation of novel sequence modifications that confer stronger
immunostimulatory effects, bi-functional siRNAs can be developed
as a single molecule approach with multiple activities. This could be
a promising anti-tumour therapeutic strategy, including targeting
HPV-driven cancers.
9.8
Conclusion
Clinically, siRNA therapies have proven disappointing. Novel
approaches to delivery and efficacy will be required to push RNAi
into the clinic. The HFDM and PLAS systems show promise in
bridging the bench-to-bedside divide.
References
1. Fire, A.,
, Potent and specific genetic interference by double-
stranded RNA in Caenorhabditis elegans.
et al.
Nature
, 1998.
391
(6669):
pp. 806
-
811.
2. Gao, S.,
, The effect of chemical modification and nanoparticle
formulation on stability and biodistribution of siRNA in mice.
et al.
Mol
Ther
, 2009.
17
(7): pp. 1225
-
1233.
3. Soutschek, J.,
, Therapeutic silencing of an endogenous gene
by systemic administration of modified siRNAs.
et al.
Nature
, 2004.
432
178.
4. Watts, J.K., G.F. Deleavey, and M.J. Damha, Chemically modified
siRNA: tools and applications.
(7014): pp. 173
-
Drug Discov Today
, 2008.
13
(19
-
20):
855.
5. Yuan, H.,
pp. 842
-
, Effects of cholesterol-tagged small interfering RNAs
targeting 12/15-lipoxygenase on parameters of diabetic nephropathy
in a mouse model of type 1 diabetes.
et al.
Am J Physiol Renal Physiol
, 2008.
295
(2): pp. F605
-
617.
Search WWH ::
Custom Search